Bromfed Dosing for 29.94 kg Child
Bromfed (brompheniramine/dextromethorphan/pseudoephedrine combination) should NOT be used in this child based on FDA labeling and safety data, as these combination products are not recommended for routine use in pediatric patients due to significant toxicity risks and lack of proven efficacy.
Critical Safety Considerations
The FDA drug label explicitly warns about serious toxicity from this combination product 1. The evidence demonstrates:
- Brompheniramine toxicity: A 2½-year-old child survived 300-900 mg of brompheniramine, but this represents a massive overdose with unpredictable individual responses 1
- Dextromethorphan toxicity: Seizures have occurred in children at doses of 13-17 mg/kg, and a 2½-year-old exhibited ataxia, drowsiness, and fever at 21 mg/kg 1
- Fatal outcomes documented: A case report describes infant fatality from this exact combination (pseudoephedrine 14.4 mg/L blood, brompheniramine 0.40 mg/L, dextromethorphan 0.50 mg/L) 2
Why This Medication Should Be Avoided
For a 29.94 kg child, the risks substantially outweigh any potential benefits:
Unpredictable toxicity: The FDA label states "individuals may respond in an unexpected manner to apparently small amounts of a particular drug" 1
CNS effects: The combination can cause agitated psychosis, ataxia, hyperirritability, and seizures even with therapeutic dosing 3
Lack of efficacy data: Widespread use of pseudoephedrine and phenylpropanolamine in children "should be reevaluated" due to lack of objective evidence 4
Dextromethorphan referral threshold: Evidence-based guidelines recommend emergency department referral for ingestions >7.5 mg/kg 5
If Absolutely Required (Against Recommendation)
If a prescriber insists on using this medication despite the above warnings, extreme caution is mandatory:
Dextromethorphan: Maximum 5-7.5 mg/kg with close monitoring 5
- For 29.94 kg: 150-225 mg maximum (but this approaches toxic range)
Monitor closely for CNS stimulation (pseudoephedrine), anticholinergic effects (brompheniramine), and CNS depression or seizures (dextromethorphan) 1
Follow-up every 2 hours for 4 hours after administration 5
Preferred Alternatives
Rather than using this combination product, consider:
- Single-agent therapy targeting the specific symptom
- Non-pharmacologic interventions
- Age-appropriate alternatives with better safety profiles
Overdose Recognition
Seek emergency care immediately if the child develops:
- Drowsiness, ataxia, or seizures (dextromethorphan toxicity)
- Tachycardia, hypertension, or agitation (pseudoephedrine toxicity)
- Anticholinergic signs or CNS stimulation alternating with depression 1
Treatment includes naloxone 0.005 mg/kg IV for CNS depression from dextromethorphan and supportive care 1.